| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $26.9M | -41.8% |
| SG&A Expense | $32.2M | -14.6% |
| Operating Income | -$59.1M | +29.6% |
| Net Income | -$57.4M | +28.3% |
| EPS (Basic) | -$1.45 | +45.3% |
| EPS (Diluted) | -$1.45 | +45.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.5M | -9.3% |
| Short-term Investments | $89.5M | +118.0% |
| Current Assets | $94.0M | +105.2% |
| Total Assets | $94.0M | +105.2% |
| Current Liabilities | $6.4M | -37.5% |
| Total Liabilities | $7.5M | -27.2% |
| Stockholders' Equity | $86.5M | +143.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$45.8M | +11.5% |
| Investing Cash Flow | -$48.1M | -193.4% |
| Financing Cash Flow | $93.6M | — |